The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Novo Nordisk A/S

NYSE: NVO
Last

(U.S.) $56.39

Today's change+1.42 +2.58%
Updated May 25 12:46 PM EDT. Delayed by at least 15 minutes.
 

Novo Nordisk A/S

NYSE: NVO
Last

(U.S.) $56.39

Today's change+1.42 +2.58%
Updated May 25 12:46 PM EDT. Delayed by at least 15 minutes.

Novo Nordisk A/S crosses above 50-day moving average

Novo Nordisk A/S is up sharply today, rallying (U.S.)$1.42 or 2.58% to (U.S.)$56.39 and crossing above its 50-day moving average. Over the last five days, shares have gained 3.83%, but are currently unchanged over the last year to date. Shares have performed in-line with the S&P 500 during the last year.

Key company metrics

  • Open(U.S.) $56.55
  • Previous close(U.S.) $54.97
  • High(U.S.) $56.59
  • Low(U.S.) $56.15
  • Bid / Ask(U.S.) $56.38 / (U.S.) $56.39
  • YTD % change-2.91%
  • Volume797,103
  • Average volume (10-day)1,247,800
  • Average volume (1-month)1,179,616
  • Average volume (3-month)1,499,487
  • 52-week range(U.S.) $46.17 to (U.S.) $60.34
  • Beta0.79
  • Trailing P/E27.86×
  • P/E 1 year forward41.39×
  • Forward PEG3.54×
  • Indicated annual dividend(U.S.) $0.96
  • Dividend yield1.70%
  • Trailing EPS(U.S.) $2.02
Updated May 25 12:46 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+31.33%

Based on its net profit margin of 31.33%, Novo Nordisk A/S is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.82%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2016Q4/2015Q3/2015Q2/2015
Fiscal Quarter Endvalues in $ millions unless otherwise notedMar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015
Revenue27,21228,87626,79227,059
Total other revenue--------
Total revenue27,21228,87626,79227,059
Gross profit22,97824,26822,94523,200
Total cost of revenue4,2344,6083,8473,859
Total operating expense14,90317,75114,81214,577
Selling / general / administrative7,6499,2037,9038,062
Research & development3,3044,0343,2893,035
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)0000
Other operating expenses, total-284-94-227-379
Operating income12,30911,12511,98012,482
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax11,95310,31410,13610,548
Income after tax9,4558,2588,3838,343
Income tax, total2,4982,0561,7532,205
Net income9,4558,2588,3838,343
Total adjustments to net income--------
Net income before extra. items9,4558,2588,3838,343
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items9,4558,2588,3838,343
Inc. avail. to common incl. extra. items9,4558,2588,3838,343
Diluted net income9,4558,2588,3848,343
Dilution adjustment0--1--
Diluted weighted average shares2,5502,5512,5722,584
Diluted EPS excluding extraordinary itemsvalue per share3.713.243.263.23
Dividends per sharevalue per share0.006.400.000.00
Diluted normalized EPSvalue per share3.713.243.263.23